In the last week, we have been hit by headlines that MSD plans to close its discovery research activities in London and that AstraZeneca is pausing investment due to the UK commercial environment and specifically in response to VPAG outcomes.
Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, has garnered widespread media attention1 this week following a renewed focus on the impact of its Brainomix 360 Stroke technology to improve recovery rates for stroke patients.
In this blog, Albert Maguire-King, Media and Communications Executive at the BIA, shares the vision of hope witnessed at BIA's recent TechBio X event in Cambridge.
In this blog, Sarah Potter, Partner - Patent Attorney and Robert Cogger-Ward, Associate at Potter Clarkson, share what you need to know about DSI and the Cali Fund.
Brainomix and 3DR Labs announced a new strategic partnership to support acute stroke care in the US through the clinically validated and FDA-cleared Brainomix 360 Stroke.
Tailor Bio announced the publication of a pivotal study demonstrating the power of chromosomal instability (CIN) signatures to predict resistance to widely used chemotherapy drugs across multiple cancer types.
Symbiotic.blue, the UK’s newest Techbio company has launched to innovate a next-generation artificial intelligence-driven drug discovery (AIDD) platform by combining the power of generative AI with brain-inspired methodologies.
Since joining the TechBio Boost programme, SokerData has refined its business model, adopted a more strategic approach to market entry, built new partnerships and is securing funding to accelerate R&D and commercialisation.
BIA publishes its 10-year Vision for the UK life science sector, the culmination of 18 months of research and engagement with members and the broader life science ecosystem.
Welcome to our new-look quarterly report, where the BIA team share examples of the influence we are delivering for members on government policy and the global life sciences ecosystem.
Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline.
A new partnership with ARC West London, designed to support innovators across AI, life sciences, robotics and digital industries to scale, bolstering the West London life sciences ecosystem.
University of Oxford spinout accelerates commercial expansion in the US of its innovative stroke AI imaging solution, with its demonstrated impact on vital treatments.
We've responded to the joint Intellectual Property Office (IPO), Department for Science, Innovation and Technology (DSIT) and Department for Culture, Media, and Sport (DCMS) consultation on Copyright and Artificial Intelligence (AI).
